Stress reduction in the secondary prevention of cardiovascular disease: Randomized, controlled trial of transcendental meditation and health education in blacks

Circulation: Cardiovascular Quality and Outcomes

Volumn 5, Issue 6, 2012, Pages 750-758

  Schneider, Robert H ^a,b   Grim, Clarence E ^c   Rainforth, Maxwell V ^a,b   Kotchen, Theodore ^c   Nidich, Sanford I ^a,b   Gaylord King, Carolyn ^a,b   Salerno, John W ^a,b   Kotchen, Jane Morley ^c   Alexander, Charles N ^a  

^a MAHARISHI UNIVERSITY OF MANAGEMENT   (United States)

^b Maharishi University of Management Research Institute   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cardiovascular disease; Complementary therapies; Health status disparities; Integrative medicine; Meditation; Mind body therapies; Stress

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDITATION; MENTAL STRESS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SURVIVAL;

AFRICAN AMERICANS; AGED; CORONARY DISEASE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDITATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PATIENT EDUCATION AS TOPIC; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; STRESS, PSYCHOLOGICAL; STROKE; TIME FACTORS; TREATMENT OUTCOME; WISCONSIN;

EID: 84873628261     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.112.967406     Document Type: Article

References (73)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Mackay J, Mensah GA, Mendis S, Greenlund K. The Atlas of Heart Disease and Stroke, 2004, World Health Statistics. Geneva, Switzerland: World Health Organization; 2009.
3. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233-1241.
4. Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol. 2008;51:1237-1246.
5. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: The emerging field of behavioral cardiology. J Am Coll Cardiol. 2005;45:637-651.
6. Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress. Lancet. 2007;370:1089-1100.
7. Bairey Merz CN, Dwyer J, Nordstrom CK, Walton KG, Salerno JW, Schneider RH. Psychosocial stress and cardiovascular disease: pathophysiological links. Behav Med. 2002;27:141-147.
8. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
9. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66:802-813.
10. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol. 2009;53:936-946.
11. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol. 2010;56:38-46.
12. Wyatt SB, Williams DR, Calvin R, Henderson FC, Walker ER, Winters K. Racism and cardiovascular disease in African Americans. Am J Med Sci. 2003;325:315-331.
13. Clark R, Anderson NB, Clark VR, Williams DR. Racism as a stressor for African Americans. A biopsychosocial model. Am Psychol. 1999;54:805-816.
14. Roberts CB, Vines AI, Kaufman JS, James SA. Cross-sectional association between perceived discrimination and hypertension in African-American men and women: The Pitt County Study. Am J Epidemiol. 2008;167:624-632.
15. Whitfield KE, Weidner G, Clark R, Anderson NB. Sociodemographic diversity and behavioral medicine. J Consult Clin Psychol. 2002;70:463-481.
16. Barnes V, Schneider R, Alexander C, Staggers F. Stress, stress reduction, and hypertension in African Americans: an updated review. J Natl Med Assoc. 1997;89:464-476.
17. Anderson JW, Liu C, Kryscio RJ. Blood pressure response to Transcendental Meditation a meta-analysis. Am J Hypertens. 2008;21:310-316.
18. Rainforth MV, Schneider RH, Nidich SI, Gaylord-King C, Salerno JW, Anderson JW. Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis. Curr Hypertens Rep. 2007;9:520-528.
19. Paul-Labrador M, Polk D, Dwyer JH, Velasquez I, Nidich S, Rainforth M, Schneider R, Merz CN. Effects of a randomized controlled trial of Transcendental Meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch Intern Med. 2006;166:1218-1224.
20. Zamarra JW, Schneider RH, Besseghini I, Robinson DK, Salerno JW. Usefulness of the Transcendental Meditation program in the treatment of patients with coronary artery disease. Am J Cardiol. 1996;78:77-80.
21. Castillo-Richmond A, Schneider RH, Alexander CN, Cook R, Myers H, Nidich S, Haney C, Rainforth M, Salerno J. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke. 2000;31:568-573.
22. Schneider RH, Alexander CN, Staggers F, Rainforth M, Salerno JW, Hartz A, Arndt S, Barnes VA, Nidich SI. Long-term effects of stress reduction on mortality in persons > or = 55 years of age with systemic hypertension. Am J Cardiol. 2005;95:1060-1064.
23. Walton KG, Schneider RH, Nidich S. Review of controlled research on the Transcendental Meditation program and cardiovascular disease. Risk factors, morbidity, and mortality. Cardiol Rev. 2004;12:262-266.
24. Barnes VA, Orme-Johnson DW. Prevention and treatment of cardiovascular disease in adolescents and adults through the Transcendental Meditation program: A research review update. Curr Hypertens Rev. 2012;8:227-242..
25. D'Agostino RB Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. 2008;117:743-753.
26. National Cholesterol Education Program. Classification, Prevalence, Detection, Evaluation. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Washington, D.C.: National Institutes of Health-National Heart, Lung, and Blood Institute; 1993:I-1-I-21.
27. Powell LH, Calvin JE Jr., Mendes de Leon CF, Richardson D, Grady KL, Flynn KJ, Rucker-Whitaker CS, Janssen I, Kravitz G, Eaton C; Heart Failure Adherence and Retention Trial Investigators. The Heart Failure Adherence and Retention Trial (HART): design and rationale. Am Heart J. 2008;156:452-460.
28. Edlavitch SA, Baxter J. Comparability of mortality follow-up before and after the National Death Index. Am J Epidemiol. 1988;127:1164-1178.
29. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, Hennekens CH. Test of the National Death Index. Am J Epidemiol. 1984;119:837-839.
30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288:2981-2997.
31. Boucher B, Cotterchio M, Kreiger N, Nadalin V, Block T, Block G. Validity and reliability of the Block98 food-frequency questionnaire in a sample of Canadian women. Public Health Nutr. 2006;9:84-93.
32. Elmer PJ, Grimm R Jr., Laing B, Grandits G, Svendsen K, Van Heel N, Betz E, Raines J, Link M, Stamler J. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med. 1995;24:378-388.
33. Folsom AR, Caspersen CJ, Taylor HL, Jacobs DR Jr., Luepker RV, Gomez-Marin O, Gillum RF, Blackburn H. Leisure time physical activity and its relationship to coronary risk factors in a population-based sample. The Minnesota Heart Survey. Am J Epidemiol. 1985;121:570-579.
34. Radloff L. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;3:385-401.
35. Long Foley K, Reed PS, Mutran EJ, DeVellis RF. Measurement adequacy of the CES-D among a sample of older African-Americans. Psychiatry Res. 2002;109:61-69.
36. Barefoot JC, Dodge KA, Peterson BL, Dahlstrom WG, Williams RB Jr. The Cook-Medley hostility scale: item content and ability to predict survival. Psychosom Med. 1989;51:46-57.
37. Nabi H, Singh-Manoux A, Ferrie JE, Marmot MG, Melchior M, Kivimäki M. Hostility and depressive mood: results from the Whitehall II prospective cohort study. Psychol Med. 2010;40:405-413.
38. Spielberger C, Sydeman S, Owen A, Marsh B. Measuring anxiety and anger with the State-Trait Anxiety Inventory (STAI) and the State-Trait Anger Expression Inventory (STAXI). In: Maruish M, ed. The Use of Psychological Testing for Treatment Planning and Outcomes Assessment. Mahwah, NJ: Lawrence Erlbaum Associates; 1999:1507.
39. Alexander CN, Langer EJ, Newman RI, Chandler HM, Davies JL. Transcendental Meditation mindfulness, and longevity: an experimental study with the elderly. J Pers Soc Psychol. 1989;57:950-964.
40. Roth R. Maharishi Mahesh Yogi's Transcendental Meditation. Washington, DC: Primus; 2002.
41. Walton KG, Schneider RH, Salerno JW, Nidich SI. Psychosocial stress and cardiovascular disease. Part 3: Clinical and policy implications of research on the Transcendental Meditation program. Behav Med. 2005;30:173-183.
42. Schneider RH, Alexander CN, Salerno JW, Robinson DK Jr., Fields JZ, Nidich SI. Disease prevention and health promotion in the aging with a traditional system of natural medicine: Maharishi Vedic Medicine. J Aging Health. 2002;14:57-78.
43. Sharma H, Clark C. Ayurvedic Healing: Contemporary Maharishi Ayurveda Medicine and Science. London, UK: Singing Dragon Publications, 2012.
44. Rosenthal N. Transcendence: Healing and Transformation Through Transcendental Meditation. New York, NY: Penguin-Tarcher; 2011.
45. Travis F. Transcendental Meditation technique. In: Craighead W, Nemeroff C, eds. The Corsini Encyclopedia of Psychology and Behavioral Science. New York, NY: John Wiley and Sons; 2001:1705-1706.
46. Jevning R, Wallace RK, Beidebach M. The physiology of meditation: a review. A wakeful hypometabolic integrated response. Neurosci Biobehav Rev. 1992;16:415-424.
47. Travis F, Shear J. Focused attention, open monitoring and automatic self-transcending: Categories to organize meditations from Vedic, Buddhist and Chinese traditions. Conscious Cogn. 2010;19:1110-1118.
48. Walton KG, Schneider RH, Nidich SI, Salerno JW, Nordstrom CK, Bairey Merz CN. Psychosocial stress and cardiovascular disease Part 2: effectiveness of the Transcendental Meditation program in treatment and prevention. Behav Med. 2002;28:106-123.
49. Windsor R, Baranowski T, Clark N, Cutter G. Evaluation of Health Promotion, Health Education and Disease Prevention Programs. Mountainview, CA: Mayfield Publishing Co; 1994.
50. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
51. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, and treatment of high blood cholesterol in adults (Adult Treatment Panel III),. Final Report. Circulation. 2002;106:3143-3421.
52. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21:2917-2930.
53. Committee for Proprietary Medicinal Products. Points to Consider on Adjustment for Baseline Covariates 2863/2899. London, UK: The European Agency for the Evaluation of Medicinal Products; 2003.
54. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics. 1995;51:1315-1324.
55. Alexander CN, Schneider RH, Staggers F, Sheppard W, Clayborne BM, Rainforth M, Salerno J, Kondwani K, Smith S, Walton KG, Egan B. Trial of stress reduction for hypertension in older African Americans. II. Sex and risk subgroup analysis. Hypertension. 1996;28:228-237.
56. Schneider RH, Alexander CN, Staggers F, Orme-Johnson DW, Rainforth M, Salerno JW, Sheppard W, Castillo-Richmond A, Barnes VA, Nidich SI. A randomized controlled trial of stress reduction in African Americans treated for hypertension for over one year. Am J Hypertens. 2005;18:88-98.
57. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
58. Mills PJ, Schneider RH, Hill D, Walton KG, Wallace RK. Beta-adrenergic receptor sensitivity in subjects practicing Transcendental Meditation. J Psychosom Res. 1990;34:29-33.
59. Barnes VA, Kapuku GK, Treiber FA. Impact of Transcendental Meditation on left ventricular mass in African American adolescents. Evid Based Complement Alternat Med. 2012;2012:923153.
60. Jayadevappa R, Johnson JC, Bloom BS, Nidich S, Desai S, Chhatre S, Raziano DB, Schneider R. Effectiveness of Transcendental Meditation on functional capacity and quality of life of African Americans with congestive heart failure: a randomized control study. Ethn Dis. 2007;17:72-77.
61. Travis F, Wallace RK. Autonomic and EEG patterns during eyes-closed rest and Transcendental Meditation practice: The basis for a neural model of TM practice. Conscious Cogn. 1999;8:302-318.
62. Travis F, Haaga DA, Hagelin J, Tanner M, Nidich S, Gaylord-King C, Grosswald S, Rainforth M, Schneider RH. Effects of Transcendental Meditation practice on brain functioning and stress reactivity in college students. Int J Psychophysiol. 2009;71:170-176.
63. Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol. 2009;169:1158-1165.
64. Friedman M, Thoresen CE, Gill JJ, Ulmer D, Powell LH, Price VA, Brown B, Thompson L, Rabin DD, Breall WS Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients: summary results of the recurrent coronary prevention project. Am Heart J. 1986;112:653-665.
65. Jones DA, West RR. Psychological rehabilitation after myocardial infarction: multicentre randomised controlled trial. BMJ. 1996;313:1517-1521.
66. Writing Committee for the ENRICHD Investigators. Effects of treating depression and low level social support on clinical events after myocardial infarction: The Enhancing Recovery in Coronary Heart Disease (ENRICHD) patients randomized trial. JAMA. 2003;289:3106-3116.
67. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svärdsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med. 2011;171:134-140.
68. Orth-Gomér K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: The Stockholm Women's Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes. 2009;2:25-32.
69. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885-888.
70. Keech A, Gebski V, Pike R, eds. Interpreting and Reporting Clinical Trials: A Guide to the CONSORT Statement and the Principles of Randomized Controlled Trials. Sydney, Australia: Australasian Medical Publishing Co; 2007:27 71.
71. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med. 2001;161:277-284.
72. Ravakhah K. Death certificates are not reliable: revivification of the autopsy. South Med J. 2006;99:728-733.
73. Orme-Johnson DW, Walton KG. All approaches to preventing or reversing effects of stress are not the same. Am J Health Promot. 1998; 12:297-299.